Immunic

Immunic received a Notice of Allowance from the USPTO for its fifth US patent covering vidofludimus calcium dose strengths of 10-45 mg daily for progressive multiple sclerosis treatment.

IMU-856, an oral SIRT6 modulator, demonstrated significant dose-dependent increases in GLP-1 levels up to 250% versus placebo in celiac disease patients during Phase 1b trial.

Immunic's phase 2 CALLIPER trial of Vidofludimus Calcium in progressive multiple sclerosis is expected to report top-line data in April.

The multiple sclerosis (MS) therapeutic landscape is expanding, with over 80 active pipeline therapies currently in development by more than 75 companies.

Immunic's IMU-856, a SIRT6 modulator, demonstrated positive clinical signals in a Phase 1/1b trial for celiac disease, showing potential in restoring gut health.

Immunic's Phase 3 ENSURE program for relapsing multiple sclerosis (RMS) continues as planned after a positive interim analysis by the Independent Data Monitoring Committee.

Immunic's phase 3 ENSURE program for vidofludimus calcium in relapsing multiple sclerosis (RMS) continues as planned after a positive interim futility analysis.

Immunic's phase 3 ENSURE program, evaluating vidofludimus calcium for relapsing multiple sclerosis (RMS), will continue as planned after a positive IDMC review.

Immunic's ENSURE program, consisting of two Phase 3 trials evaluating vidofludimus calcium for relapsing multiple sclerosis (RMS), will proceed without modifications.

Immunic's vidofludimus calcium is under investigation in Phase 3 trials for relapsing MS and Phase 2 for progressive MS, targeting both inflammation and neuroprotection.